Study Evaluating Effexor XR for Major Depression.

Phase 3CompletedNCT00225511

Wyeth is now a wholly owned subsidiary of Pfizer590 enrolled

Overview

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

590

Conditions

Depression

Interventions

Effexor XRDRUG

MilnacipranDRUG

Eligibility

Sex: ALLMin age: 20 YearsMax age: 64 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients diagnosed with major depression based on DSM-IV-TR * Patients having minimal total score of 18 on the HAM-D17 and minimal score of 2 on the item of "depressed mood" at the baseline. Exclusion Criteria: * Patients with schizophrenia or any other psychotic disorder * Patients with history or presence of bipolar disorder

Locations (73)

Outcomes

Primary Outcomes

Response rate of HAM-D17 (Hamilton Rating Scale for Depression) at the final-on-therapy.

Secondary Outcomes

Difference of total score of HAM-D17 between baseline and final-on-therapy.

Remission rate of HAM-D17 at the final-on-therapy.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Unnamed facility

Nagoya, Aichi-ken, Japan

Unnamed facility

Nagoya, Aichi-ken, Japan

Unnamed facility

Ichikawa, Chiba, Japan

Unnamed facility

Ichikawa, Chiba, Japan

Unnamed facility

Fukuoka, Fukuoka, Japan

Unnamed facility

Fukuoka, Fukuoka, Japan

Unnamed facility

Fukuoka, Fukuoka, Japan

Unnamed facility

Fukuoka, Fukuoka, Japan

Unnamed facility

Kasuga, Fukuoka, Japan

Unnamed facility

Kitakyushu, Fukuoka, Japan

...and 63 more locations